TNFRSF17 and neoplasm: These anti-BCMA CAR-T cells were also tested in human subjects in a phase I trial, and anti-BCMA CAR-T was successful in all the patients and achieved an overall response rate of 88.2% and sustained tumor remissions up to 12.5 months after therapy.